Mark Leuchtenberger, President and Chief Executive Officer
Mark Leuchtenberger joined Rib-X in March, 2010, as the Chief Executive Officer, bringing significant expertise in commercial operations, business development and preparing biopharma companies for product approval and commercialization. Prior to joining Rib-X, he served as President and CEO of Targanta Therapeutics Corporation and led the company's successful IPO in 2007 and acquisition in 2009. He joined Targanta from Therion Biologics Corporation, a privately-held cancer vaccine company, where he served as President and CEO and led the company's lead product through development and commercial manufacturing build-up and raised over $120 million in private financing. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen, where he led the Avonex development and launch in the U.S. and subsequently ran North American and international commercial operations. Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University. He currently serves on the Executive Committee of the MassBio Board of Directors and as a trustee for Beth Israel Deaconess Medical Center. He is a co-founder of Albor Biologics and Mercator Therapeutics.